Results 221 to 230 of about 144,997 (264)

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis

open access: yesCancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Nivolumab plus ipilimumab has shown survival benefits as first‐line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost‐effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer ...
Jiefeng Luo   +8 more
wiley   +1 more source

Economic and Technical Assessment of Wind Potential Using SARIMAX Time Series Models: Wind Speed Forecasting and Analysis

open access: yesEnergy Science &Engineering, Volume 14, Issue 2, Page 973-998, February 2026.
The wind energy potential of Khaf was evaluated for 2025 using 15 years of wind data combined with advanced forecasting models, SARIMAX and Prophet. This integrated framework enables precise estimation of wind power density and optimal turbine selection, paving the way for the efficient and sustainable development of wind farms in the region.
Mohammad Amin Valizadeh   +3 more
wiley   +1 more source

Application of the Weibull Model to Statins for Triglyceride Management in Patients With Hyperlipidaemia. [PDF]

open access: yesPharmacol Res Perspect
Nakayama N   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy